INOVIO PHARMACEUTICALS, INC. (INO) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
34/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseINO / S&P -36.78% / 15.20% |
LoseINO / S&P -100.00% / 15.00% |
LoseINO / S&P -65.13% / 50.40% |
| 2026-Q11/3 |
WinINO / S&P 0.00% / -4.33% |
LoseINO / S&P -100.00% / 11.30% |
LoseINO / S&P -54.55% / 27.70% |
| 2025-Q40/3 |
LoseINO / S&P -25.64% / 2.65% |
LoseINO / S&P -69.99% / 9.00% |
LoseINO / S&P -57.89% / 13.40% |
| 2025-Q31/3 |
WinINO / S&P 14.71% / 8.12% |
LoseINO / S&P -10.36% / 4.61% |
LoseINO / S&P -42.06% / 13.45% |
| 2025-Q21/3 |
WinINO / S&P 25.15% / 10.94% |
LoseINO / S&P -69.19% / 4.83% |
LoseINO / S&P -48.82% / 10.63% |
| 2025-Q10/3 |
LoseINO / S&P -10.93% / -4.27% |
LoseINO / S&P -60.52% / 4.98% |
LoseINO / S&P -42.21% / 10.57% |
| 2024-Q40/3 |
LoseINO / S&P -68.34% / 2.41% |
LoseINO / S&P -73.83% / 5.25% |
LoseINO / S&P -34.59% / 6.15% |
| 2024-Q30/3 |
LoseINO / S&P -28.47% / 5.89% |
LoseINO / S&P -76.18% / 5.89% |
LoseINO / S&P -75.34% / 6.11% |
| 2024-Q20/3 |
LoseINO / S&P -41.79% / 4.28% |
LoseINO / S&P -93.85% / 5.38% |
LoseINO / S&P -69.57% / 5.12% |
| 2024-Q11/3 |
WinINO / S&P 126.80% / 10.56% |
LoseINO / S&P -92.95% / 5.71% |
LoseINO / S&P -64.64% / 5.59% |
| 2023-Q41/3 |
WinINO / S&P 30.77% / 11.69% |
LoseINO / S&P -91.89% / 6.81% |
LoseINO / S&P -56.68% / 7.78% |
| 2023-Q31/3 |
LoseINO / S&P -13.33% / -3.27% |
LoseINO / S&P -92.22% / 7.52% |
WinINO / S&P 3.78% / -5.03% |
| 2023-Q22/3 |
LoseINO / S&P -45.12% / 8.74% |
WinINO / S&P 354.99% / 9.50% |
WinINO / S&P -4.83% / -8.57% |
| 2023-Q12/3 |
LoseINO / S&P -47.44% / 7.50% |
WinINO / S&P 535.06% / 10.77% |
WinINO / S&P -11.00% / -15.69% |
| 2022-Q41/3 |
LoseINO / S&P -9.83% / 7.56% |
WinINO / S&P 478.24% / 11.88% |
LoseINO / S&P -19.31% / -17.99% |
| 2022-Q33/3 |
WinINO / S&P 0.00% / -4.88% |
WinINO / S&P 68.45% / 13.47% |
WinINO / S&P 1548.11% / -1.41% |
| 2022-Q21/3 |
LoseINO / S&P -51.81% / -16.10% |
LoseINO / S&P -67.27% / 13.71% |
WinINO / S&P 2568.18% / 11.04% |
| 2022-Q11/3 |
LoseINO / S&P -28.06% / -4.60% |
LoseINO / S&P -75.17% / 15.97% |
WinINO / S&P 1494.55% / 42.23% |
| 2021-Q40/3 |
LoseINO / S&P -30.31% / 11.03% |
LoseINO / S&P -76.05% / 15.00% |
LoseINO / S&P INO unavailable / 96.40% |
| 2021-Q31/3 |
LoseINO / S&P -22.76% / 0.58% |
WinINO / S&P 208.81% / 10.77% |
LoseINO / S&P INO unavailable / 69.42% |
| 2021-Q21/3 |
LoseINO / S&P -0.11% / 8.55% |
WinINO / S&P 135.72% / 6.58% |
LoseINO / S&P INO unavailable / 51.81% |
| 2021-Q11/3 |
LoseINO / S&P 4.86% / 6.17% |
WinINO / S&P 147.39% / -1.06% |
LoseINO / S&P INO unavailable / 7.39% |
| 2020-Q41/3 |
LoseINO / S&P -23.71% / 12.15% |
WinINO / S&P 80.24% / -3.72% |
LoseINO / S&P INO unavailable / -33.42% |
| 2020-Q30/3 |
LoseINO / S&P -56.96% / 8.93% |
LoseINO / S&P -66.69% / -2.04% |
LoseINO / S&P INO unavailable / -27.10% |
| 2020-Q21/3 |
WinINO / S&P 262.23% / 20.54% |
LoseINO / S&P -63.30% / -0.46% |
LoseINO / S&P INO unavailable / -27.11% |
| 2020-Q11/3 |
WinINO / S&P 125.45% / -19.60% |
LoseINO / S&P -91.79% / 3.47% |
LoseINO / S&P INO unavailable / -14.75% |
| 2019-Q41/3 |
WinINO / S&P 60.98% / 9.07% |
LoseINO / S&P -86.51% / 5.36% |
LoseINO / S&P INO unavailable / 2.99% |
| 2019-Q30/3 |
LoseINO / S&P -30.27% / 1.70% |
LoseINO / S&P -82.77% / 5.02% |
LoseINO / S&P INO unavailable / 0.21% |
| 2019-Q20/3 |
LoseINO / S&P -21.18% / 4.30% |
LoseINO / S&P -80.03% / 6.64% |
LoseINO / S&P INO unavailable / 8.65% |
| 2019-Q10/3 |
LoseINO / S&P -6.75% / 13.65% |
LoseINO / S&P -4.77% / 8.12% |
LoseINO / S&P INO unavailable / 14.29% |
| 2018-Q40/3 |
LoseINO / S&P -28.06% / -13.52% |
LoseINO / S&P -27.80% / 9.05% |
LoseINO / S&P -1.85% / 18.23% |
| 2018-Q31/3 |
WinINO / S&P 41.84% / 7.71% |
LoseINO / S&P -12.35% / 10.21% |
LoseINO / S&P -20.83% / 19.06% |
| 2018-Q20/3 |
LoseINO / S&P -16.77% / 3.43% |
LoseINO / S&P -27.84% / 9.03% |
LoseINO / S&P 0.00% / 14.46% |
| 2018-Q11/3 |
WinINO / S&P 14.04% / -0.76% |
LoseINO / S&P -11.32% / 7.68% |
LoseINO / S&P -6.61% / 12.46% |
| 2017-Q41/3 |
LoseINO / S&P -34.86% / 6.64% |
WinINO / S&P 19.37% / 7.03% |
LoseINO / S&P 6.93% / 13.82% |
| 2017-Q32/3 |
LoseINO / S&P -19.13% / 4.48% |
WinINO / S&P 27.93% / 5.68% |
WinINO / S&P 31.87% / 17.57% |
| 2017-Q23/3 |
WinINO / S&P 18.43% / 3.09% |
WinINO / S&P 16.68% / 4.83% |
WinINO / S&P 92.86% / 17.74% |
| 2017-Q11/3 |
LoseINO / S&P -4.61% / 6.07% |
LoseINO / S&P -13.52% / 3.67% |
WinINO / S&P 210.26% / 13.32% |
| 2016-Q41/3 |
LoseINO / S&P -25.54% / 3.82% |
LoseINO / S&P -12.83% / 2.09% |
WinINO / S&P 119.57% / 7.05% |
| 2016-Q31/3 |
LoseINO / S&P 0.87% / 3.85% |
LoseINO / S&P -11.60% / 0.20% |
WinINO / S&P 184.38% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | INO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -46.84% | 20.78% |
| Annualized return | -46.84% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | INO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.80% | 83.14% |
| Annualized return | -58.70% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | INO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.85% | 319.30% |
| Annualized return | -36.02% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |